Editor of Patient Care Online.
Johann Gudjonsson, MD, PhD, on Emerging AD Therapies: From Single Targets to Combination Approaches
June 19th 2025RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.